Elanco Animal Health (NYSE:ELAN) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Elanco Animal Health (NYSE:ELAN) announced its earnings results on Wednesday. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06, FiscalAI reports. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the business earned $0.37 earnings per share. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health updated its Q2 2026 guidance to 0.250-0.285 EPS and its FY 2026 guidance to 1.030-1.090 EPS.

Here are the key takeaways from Elanco Animal Health’s conference call:

• Raised guidance: Elanco increased full-year targets to 5%-7% organic growth, adjusted EBITDA of $975M–$1.005B, adjusted EPS of $1.03–$1.09, and raised its 2026 innovation revenue goal to $1.2B.
• Launch momentum: Innovation sales drove the quarter — Zenrelia reached blockbuster status and is now in >50% of U.S. clinics with >80% reorder rates, while Credelio Quattro is in >40% of clinics and has reached 53% share within those clinics, with rapid international rollout underway.
• Strong Q1 financials and deleveraging: Q1 revenue of $1.371B (10% organic growth) produced adjusted EBITDA of $334M (+21%) and EPS of $0.40, with net debt $3.3B (3.5x) and management tightening year-end net leverage guidance to 3.0–3.2x and targeting <3x in 2027.
• Key risks: The FDA has requested additional data for Zenrelia (company’s guidance assumes no U.S. label change), and management flagged near-term gross margin headwinds from inventory/inflation plus competitive/generic pressures that could push results toward the low end of guidance.
• Productivity program: The Elanco Ascend initiative (5,000+ projects) plus AI/automation is expected to drive margin expansion and operational efficiencies, enabling continued reinvestment in launches and a target of >$1B free cash flow through 2028.

Elanco Animal Health Trading Down 9.5%

Elanco Animal Health stock traded down $2.48 during mid-day trading on Thursday, hitting $23.70. The company’s stock had a trading volume of 6,614,680 shares, compared to its average volume of 5,003,681. The firm has a market capitalization of $11.78 billion, a PE ratio of -49.38, a price-to-earnings-growth ratio of 2.93 and a beta of 1.69. Elanco Animal Health has a 1 year low of $11.83 and a 1 year high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The stock’s fifty day moving average is $23.85 and its two-hundred day moving average is $23.33.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ELAN shares. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 18th. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, April 27th. Citigroup assumed coverage on Elanco Animal Health in a research report on Wednesday, April 15th. They issued a “buy” rating and a $30.00 price target for the company. Leerink Partners upped their price target on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Finally, UBS Group restated a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $27.90.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 beat and raised full‑year outlook — Elanco reported adjusted EPS $0.40 and revenue $1.371B, both above consensus, and raised FY 2026 revenue, adjusted EBITDA and adjusted EPS guidance while increasing its innovation revenue target. This reinforces the company’s revenue growth and margin improvement narrative. Elanco Q1 Results & Guidance
• Positive Sentiment: Product approvals and momentum — Elanco received emergency use authorizations for Negasunt Powder and Tanidil, supporting the company’s innovation-led growth story and pipeline credibility. Product Momentum Article
• Neutral Sentiment: Underlying results detail — Q1 revenue rose ~15% YoY (10% organic cc); adjusted EBITDA $334M (24.5% margin); reported net income $57M; adjusted EPS and adjusted EBITDA figures indicate operational progress but GAAP metrics still show limitations. Detailed Results
• Neutral Sentiment: Investor materials available — Earnings slide deck and full call transcript provide management color on product cadence, margin actions and leverage plan for investors doing deeper due diligence. Earnings Call Transcript Earnings Presentation
• Negative Sentiment: Q2 EPS guidance misses consensus — Management set Q2 EPS at $0.250–0.285 versus a ~0.290 consensus; this near‑term shortfall likely tempered upside despite the stronger FY view. Guidance Details
• Negative Sentiment: Leverage and GAAP profitability remain concerns — Net leverage is still elevated (reported ~3.5x) and the company reports a negative GAAP net margin, so some investors may be cautious until deleveraging and sustained free‑cash‑flow improvements are clearer. Leverage & Profitability

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ELAN. NewEdge Advisors LLC grew its position in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares during the period. Uniplan Investment Counsel Inc. purchased a new position in Elanco Animal Health in the fourth quarter worth approximately $41,000. Geneos Wealth Management Inc. grew its position in Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock worth $85,000 after acquiring an additional 2,080 shares during the period. EverSource Wealth Advisors LLC grew its position in Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock worth $91,000 after acquiring an additional 1,332 shares during the period. Finally, UMB Bank n.a. grew its position in Elanco Animal Health by 31.9% in the fourth quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock worth $127,000 after acquiring an additional 1,358 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.